AP NEWS

Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease

November 6, 2018

ROCHESTER, N.Y., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced it will be presenting abstracts on its Semaphorin 4D monoclonal antibody program at two conferences in November, one focused on Huntington’s Disease and the other cancer immunotherapy.

The abstract, “Clinical Developments of VX15 Anti-Semaphorin 4D Antibody as a Potential Treatment for Huntington’s Disease,” will be presented as a poster on November 8th at the Huntington Study Group’s 25th Annual Meeting, HSG 2018. The following day, the abstract will be presented in an oral session. The conference will be held from November 8-10, 2018 in Houston, Tex.

Subsequently, the abstract, “Reprogramming Suppressive Myeloid Cells in Tumor Microenvironment with Pepinemab, First-in-Class Semaphorin 4D MAb, Enhances Combination Immunotherapy,” will be presented in a poster at the 33rd Annual Meeting of the Society of Immunotherapy of Cancer on November 9th and 10th. Co-author Gregory Lesinski, Ph.D., M.P.H. of the Winship Cancer Institute of Emory University will also present the data at an oral session at 6:00 PM ET on November 10th. The conference will be held on November 7-11, 2018 in Washington, D.C. About Vaccinex, Inc. Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York.

About HSG 2018Over the past 20 years, the Huntington Study Group (HSG) has hosted an annual, internationally recognized forum for training and education of Huntington disease (HD) researchers and for presentation of new research findings and treatments to the worldwide community.

About the 33rd Annual Meeting of the Society for Immunotherapy in Cancer The Society for Immunotherapy of Cancer (SITC) is excited to welcome delegates to the 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) on Nov. 7–11, 2018 at the Walter E. Washington Convention Center in Washington, D.C. SITC 2018 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field.

Investor Contact Michael Rice LifeSci Advisors, LLC Phone: (646) 597-6979 E-mail: mrice@lifesciadvisors.com

Media ContactJules AbrahamJQA Partners, Inc.Phone: (917) 885-7378E-mail: jabraham@jqapartners.com

AP RADIO
Update hourly